Ceftaroline fosamil 600mg powder for solution for infusion vials
Requires a prescription from a doctor or prescriber
Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Ceftaroline fosamil
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Ceftaroline fosamil on the MHRA register
Zinforo 600mg powder for concentrate for solution for infusion vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 22 · Randomised trials: 8 · 2007–2025
Showing the 50 most relevant studies, sorted by most relevant.
Thomas M. File, Donald E. Low, Paul B. Eckburg, et al.
Journal of Antimicrobial Chemotherapy, 2011
- Ceftaroline
- Bacteria
- Ceftriaxone
Donald E. Low, Thomas M. File, Paul B. Eckburg, et al.
Journal of Antimicrobial Chemotherapy, 2011
- Ceftaroline
- Bacteria
- Ceftriaxone
Antoní Torres, Alona Kuraieva, Gregory G. Stone, et al.
European Respiratory Review, 2023
- Community-Acquired Infections
- Linezolid
- Ceftaroline
Arianna Pani, Fabrizio Colombo, F. Agnelli, et al.
International Journal of Antimicrobial Agents, 2019
- Healthcare-Associated Pneumonia
- Ceftaroline
- Anti-Bacterial Agents
Yu. M. Gomon, A. S. Petrichenko
Реальная клиническая практика: данные и доказательства, 2025
Giovanni Sotgiu, Stefano Aliberti, Andrea Gramegna, et al.
Respiratory Research, 2018
- Ceftaroline
- Anti-Bacterial Agents
- Cephalosporins
Maguy Saffouh El Hajj, Ricky D. Turgeon, Kyle John Wilby
International Journal of Clinical Pharmacy, 2017
- Ceftaroline
- Anti-Bacterial Agents
- Cephalosporins
M. Rosanova, N. Sberna, R. Lede
Archivos argentinos de pediatria, 2019
- Bacterial Infections
- Cephalosporins
- Anti-Bacterial Agents
Maria T. Rosanova, Pedro S. Aguilar, Norma Sberna, et al.
Therapeutic Advances in Infectious Disease, 2019
Marco Mantero (3531767), Stefano Aliberti (61419), Francesco Blasi (61418), et al.
2018
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
194 found
Half-life
1.60 hours
Mechanism
Ceftaroline fosamil is an antibacterial drug.
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
1.60 hours
Protein binding
20%
Volume of distribution
20.3 L
Metabolism
Elimination
6%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Acute bacterial skin and skin structure infections.
Community-acquired bacterial pneumonia.
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 799 interactions
Draize test, rabbit, eye: 100 mg/24H Moderate; Oral,
mouse: LD50 = 300 mg/kg; Oral, rabbit: LD50 = 3200 mg/kg; Oral, rat:
LD50 = 980 mg/kg.
No significant effect on QTc (corrected QT interval) interval was detected at peak plasma concentration or at any other time.
How the body processes this drug — absorption, distribution, metabolism, and elimination
ATC J01DI02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Ceftaroline fosamil
Additional database identifiers
ChemSpider
8028692
BindingDB
50482776
GenBank Gene Database
X06479
UniProt Accession
DACA_ECOLI
GenBank Gene Database
X59460
GenBank Protein Database
41216
UniProt Accession
DACB_ECOLI
GenBank Gene Database
X06480
GenBank Protein Database
41218
UniProt Accession
DACC_ECOLI
GenBank Gene Database
X02164
GenBank Protein Database
581194
UniProt Accession
PBPA_ECOLI
GenBank Gene Database
X02163
GenBank Protein Database
42468
UniProt Accession
PBPB_ECOLI
GenBank Gene Database
K00137
UniProt Accession
FTSI_ECOLI
GenBank Gene Database
X04516
GenBank Protein Database
42314
UniProt Accession
MRDA_ECOLI
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q409712), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.